A5025181359- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- COVID-19 and healthcare impacts
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Pharmaceutical studies and practices
- Biosimilars and Bioanalytical Methods
- Histiocytic Disorders and Treatments
- Antifungal resistance and susceptibility
- Eosinophilic Disorders and Syndromes
- Antibiotic Resistance in Bacteria
- Nutrition and Health in Aging
- Retinoids in leukemia and cellular processes
- Cytomegalovirus and herpesvirus research
- COVID-19 Clinical Research Studies
- Parvovirus B19 Infection Studies
- Neuroblastoma Research and Treatments
- Immune responses and vaccinations
Tata Memorial Hospital
2016-2025
Homi Bhabha National Institute
2018-2025
Advanced Centre for Treatment, Research and Education in Cancer
2021-2023
Bharati Vidyapeeth Deemed University
2020-2023
Pediatric Oncology Group
2019-2022
John Wiley & Sons (United States)
2021
Tata Medical Center
2018
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018
INHS Asvini
2001-2009
Abstract Background In the west, survival following treatment of childhood acute lymphoblastic leukaemia (ALL) approaches 90%. Outcomes in India do not exceed 70%. To address this disparity, Indian Collaborative Childhood Leukaemia group (ICiCLe) developed 2013 a contemporary protocol for uniform risk-stratified management first presentation ALL based on cytogenetics and minimal residual disease levels (MRD). A multicentre randomised clinical trial opened 2016 (ICiCLe-ALL-14) examines...
Flow-cytometric minimal residual disease (FC-MRD) monitoring is a well-established risk-stratification factor in B-lymphoblastic leukemia/lymphoma (-B-ALL) and being considered as basis for deintensification or escalation treatment protocols. However, currently practiced standard FC-MRD has limited sensitivity (up to 0.01%) higher false MRD-negative rate. Hence, highly sensitive, widely applicable, easily reproducible assay needed, which can provide reliable therapeutic modifications.A...
Multiparametric flow cytometry (MFC) is a popular technique for minimal residual disease (MRD) analysis. However, its applicability still limited to 90% of B-cell precursor acute lymphoblastic leukemia (BCPALL) due two major issues, i.e. proportion cases do not express adequate associated immunophenotype (LAIPs) with currently used markers and drug-induced antigen modulation. Hence, the incorporation additional reliable required further improvement MFC-based MRD evaluation. We studied...
Invasive fungal diseases (IFD) in children with newly diagnosed acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are poorly characterized, especially lower-middle-income countries (LMICs). This study aims to identify the incidence, risk factors, outcomes of IFD a pediatric cohort ALL/LBL. We retrospectively analyzed patients ALL/LBL between January December 2023 at tertiary cancer center India. Patients were risk-stratified treated per modified ICiCLe-ALL-14 protocol. IFDs classified as...
Abstract Background There is limited data on outcomes in cancer patients with coronavirus disease 2019 (COVID‐19) from lower middle‐income countries (LMICs). Patients and Methods This was an observational study, conducted between 12 April 10 June 2020 at Tata Memorial centre, Mumbai, undergoing systemic therapy laboratory confirmed COVID‐19. The objectives were to evaluate cumulative 30‐day all‐cause mortality, COVID‐19 attributable factors predicting time viral negativity after initial...
Background Recently, anti-CD38 monoclonal antibody (Mab) therapy has become a focus of attention as an additional/alternative option for many hematological neoplasms including T-cell acute lymphoblastic leukemia (T-ALL). It been shown that antitumor efficacy anti-CD38-Mab depends on the level CD38 expression tumor cells. Reports in T-ALL are scarce, and data effect cytotoxic chemotherapy limited to very few samples. Moreover, it lacks entirely refractory disease adult T-ALL. We report flow...
Background: Outcomes of children with acute lymphoblastic leukaemia (ALL) in the west approach 90%. Treated on same protocols, outcomes India, were ~65%.
BACKGROUND: Blood stream infections (BSI) are among the most common causes of preventable deaths in children with cancer a developing country. Knowledge its etiology as well antibiotic sensitivity is essential not only for planning antimicrobial policy, but also larger infection prevention and control measures. AIMS: To describe BSI pediatric oncology unit at tertiary center. MATERIALS AND METHODS: All samples representative sent from during period January to December, 2013 were included...
High cure rates of over 80% in childhood cancers reported from high-income countries (HICs) are not replicated low- and middle-income (LMICs). Treatment abandonment (TxA) is an important reason for this poorer outcome. We assessed the effect a holistic support group approach coupled with prospective tracking on TxA children cancer limited-resources environment.In 2010, all existing nongovernmental organizations (NGOs) working at our hospital were brought together to form pediatric foundation...
Aims L‐asparaginase is an essential medicine in the treatment of pediatric acute lymphoblastic leukemia (ALL) and quality generic formulations area concern. We compared nine available India with innovator. Methods The was assessed by measuring 72‐hour trough asparaginase activity children ALL during induction following administration 10,000 IU/m 2 L‐asparaginase. In‐vitro analysis label claim three formulations. Liquid chromatography‐mass spectrometry (LC/MS) used to determine amount host...
Background: Measurable/minimal residual disease (MRD) status is suggested as a powerful indicator of clinical-outcome in T-cell lymphoblastic leukemia/lymphoma (T-ALL). Contrary to B-cell ALL, reports on T-ALL MRD are limited and mostly based molecular methods, mainly from developed countries. Multicolor flow cytometry (MFC)-based studies very few. Clinically relevant cut-off levels ideal time-point for assessment still inconclusive. In view lack data the developing world, we evaluated...
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% patients develop life-threatening toxicities associated with cytokine release syndrome which may limit its utilization low-resource settings. To mitigate toxicity, we designed a novel humanized CAR by humanizing framework region single-chain variable fragment (scFv) derived from murine FMC63 mAb and combining it CD8α...
BACKGROUND: Infection or colonization with multidrug-resistant organisms (MDRO) is associated high mortality and morbidity. Knowledge of MDRO may help in planning empirical antibiotic approach neutropenic patients, which known to improve patient outcomes. While routine cultures are positive direct therapy only up 15% surveillance more than 90% cancer patients. AIMS: To assess the rate carrier status at presentation conversion during treatment. MATERIALS AND METHODS: Rectal swabs all...
Background: Cytogenetics is one of the most important diagnostic parameters in classification acute leukemia. Recurrent chromosomal aberrations leukemia have provided insights into molecular mechanism leukemogenesis. The variable frequencies recurrent cytogenetic markers due to ethical/racial differences been reported from Western and some Asian countries. Objective: We report data largest cohort 7209 adult pediatric patients with de novo (AL) determine prevalence various sub groups compare...
Background: Survivors of childhood cancer are at increased risk for several cardiometabolic complications. Obesity/overweight and metabolic syndrome have been widely reported in Western literature, but data from India lacking. Aims: To perform an objective assessment nutritional status a cohort survivors (CCSs) to find factors extremes status. Settings And Design: The study was retrospective chart review CCSs who attended the late effects clinic referral pediatric oncology center over period...
Measurable/minimal residual disease (MRD) status has been suggested as a powerful indicator of clinical-outcome in T-cell lymphoblastic leukemia/lymphoma (T-ALL). Multicolor flow cytometric (MFC)-based T-ALL MRD reports are limited and traditionally based on the utilization markers-of-immaturity like TdT CD99. Moreover, studies demonstrating multicolor (MFC) approach for assessment sparse. Herein, we describe an 11-marker, 10-color MFC-based method using "approach exclusion."The study...
PURPOSE To share our clinical experience with the diagnosis and management of children hematolymphoid malignancies presenting epilepsia partialis continua (EPC) as a sequelae measles infection. MATERIALS AND METHODS In December 2022, series in hemato-oncology unit presented focal status epilepticus no conclusive evidence pointing toward any underlying etiology. One such child had typical rash few weeks before onset this epilepticus. After cases similar presentation, pattern suspicious for...
ABSTRACT Pediatric chronic myeloid leukemia (pCML) is a rare childhood malignancy, representing 2%–3% of all leukemia. Tyrosine kinase inhibitors (TKIs) have greatly improved survival but pose challenges due to their long‐term effects on growth and bone health in children. We prospectively studied treatment‐free remission (TFR) 45 children with pCML phase imatinib. Eligibility criteria were as per current NCCN guidelines, less stringent qPCR monitoring scheduled every 3 months. TFR was...
Abstract Introduction In 2016, Children Oncology Group (COG) described a new high‐risk subtype of acute myeloid leukemia (AML) with distinct immunophenotypic‐signature, RAM‐phenotype (RAM‐AML). Data on clinical and laboratory features RAM‐AML are still limited to COG report only. Herein, we the clinicopathological characteristics detailed immunophenotypic patients. report, 38% belonged megakaryoblastic (AMKL)‐subtype. Hence, further compared non‐RAM‐AMKL diagnosed during same study period....